Adult polycystic ovary syndrome begins in childhood

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 16, Issue 2, 2002, Pages 263-272

  Franks, Stephen ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Androgens; Insulin resistance; Polycystic ovary syndrome; Type 2 diabetes

Indexed keywords

ANDROGEN; ANTIANDROGEN; CYPROTERONE ACETATE; DEXAMETHASONE; DIANE; ESTROGEN; FLUTAMIDE; FOLLITROPIN; GESTAGEN; GLUCOSE; GONADORELIN AGONIST; INSULIN; LUTEINIZING HORMONE; METFORMIN; NAFARELIN; ORAL CONTRACEPTIVE AGENT; PROLACTIN; TESTOSTERONE; ANDROSTENEDIONE; GONADOTROPIN; HYDROXYPROGESTERONE; PREGNENOLONE; STEROID 17,20 LYASE; STEROID 17ALPHA MONOOXYGENASE;

ADOLESCENCE; ADULT; ANDROGEN SYNTHESIS; CHILDHOOD; CLINICAL FEATURE; CONGENITAL ADRENAL HYPERPLASIA; DIAGNOSTIC VALUE; DIET RESTRICTION; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; ECHOGRAPHY; ENDOCRINE DISEASE; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; FETUS DEVELOPMENT; HEREDITY; HIRSUTISM; HORMONE DETERMINATION; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL IRREGULARITY; METABOLIC DISORDER; MOLECULAR GENETICS; NONHUMAN; OBESITY; ONSET AGE; OVARY POLYCYSTIC DISEASE; PREVALENCE; PUBERTY; REVIEW; SYMPTOMATOLOGY; WEIGHT REDUCTION; ANDROGEN RELEASE; ANDROGEN THERAPY; CALORIC RESTRICTION; IN VITRO STUDY; LUTEINIZING HORMONE RELEASE; METABOLIC ENCEPHALOPATHY;

EID: 0036034768     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.2002.0203     Document Type: Article

References (37)

1. Zawadzki JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Dunaif A, Givens JR, Haseltine FP & Merriam GR (eds) Polycystic Ovary Syndrome, pp 337-384. Oxford: Blackwell Scientific Publications, 1992.
2. Franks S. Medical Progress Article: Polycystic ovary syndrome. New England Journal of Medicine 1995; 333: 853-861.
3. Franks S. Polycystic ovary syndrome: a changing perspective. Clinical Endocrinology 1989; 31: 87-120.
4. Polson DW, Adams J, Wadsworth J & Franks S. Polycystic ovaries - a common finding in normal women. Lancet 1998; i: 870-872.
5. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism of action and implications for pathogenesis. Endocrine Reviews 1996; 18: 774-800.
6. Dahlgren E, Johansson S, Lindstedt G et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertility & Sterility 1992; 57: 505-513.
7. Wild S, Pierpoint T, McKeigue P & Jacobs HS. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clinical Endocrinology 2000; 52: 595-600.
8. Bridges NA, Cooke A, Healy MJR et al. Standards for ovarian volume in childhood and puberty. Fertility & Sterility 1993; 60: 456-460.
9. van Hooff MH, Voorhorst FJ, Kaptein MB et al. Endocrine features of polycystic ovary syndrome in a random population of 14-16 year old adolescents. Human Reproduction 1999; 14: 2223-2229.
10. Zumoff B, Freeman R. Coupey S et al. A chronobiologic abnormality in luteinizing hormone secretion in teenage girls with polycystic ovary syndrome. New England Journal of Medicine 1983; 309: 1206-1209.
11. Stanhope R, Adams J, Pringle JP et al. The evolution of polycystic ovaries in a girl with hypogonadotropic hypogonadism before puberty and during puberty induced with pulsatile gonadotropin-releasing hormone. Fertility & Sterility 1987; 47: 872-875.
12. Holly JMP, Smith CP, Dunger DB et al. Relationship between the fall in sex hormone-binding globulin and insulin-like growth factor binding protein-1. A synchronized approach to pubertal development? Clinical Endocrinology 1989; 31: 277-284.
13. Willis D, Mason H, Gilling-Smith C & Franks S. Modulation by insulin of follicle stimulating and luteinizing hormone action in human granulosa cells of normal and polycystic ovaries. Journal of Clinical Endocrinology & Metabolism 1996; 81: 302-309.
14. Lewy VD, Danadian K, Witchel SF & Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. Journal of Pediatrics 2001; 138: 38-44.
15. Chang RJ, Laufer LR, Meldrum DR et al. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. Journal of Clinical Endocrinology & Metabolism 1983; 56: 897-903.
16. Couzinet B, Le Strat N, Brailly S & Schaison G. Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease. Journal of Clinical Endocrinology & Metabolism 1986; 63: 1031-1035.
17. Steingold K, De Ziegler D, Cedars M et al. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. Journal of Clinical Endocrinology & Metabolism 1987; 65: 773-778.
18. Barnes RB, Rosenfield RL, Burstein S & Ehrmann DA. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. New England Journal of Medicine 1989; 320: 559-565.
19. Rosenfield RL, Barnes RB, Cara JF & Lucky AW. Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome. Fertility and Sterility 1990; 53: 785-791.
20. Ehrmann DA, Barnes RB & Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocrine Reviews 1995; 16: 322-353.
21. White DW, Leigh A, Wilson C et al. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. Clinical Endocrinology 1995; 42: 475-481.
22. Ibanez L, Hall JE, Potau N et al. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. Journal of Clinical Endocrinology and Metabolism 1996; 81: 4103-4107.
23. Gilling-Smith C, Story H, Rogers V & Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clinical Endocrinology 1997; 47: 93-99.
24. Gilling-Smith C, Willis DS, Beard RW & Franks S. Hypersecretion of androstenedione by isolated theca cells from polycystic ovaries. Journal of Clinical Endocrinology and Metabolism 1994; 79: 1158-1165.
25. Nelson VL, Legro RS, Strauss JF III & McAllister JM. Augmented androgen production is a stable phenotype in propagated theca cells from polycystic ovaries. Molecular Endocrinology 1999; 13: 946-957.
26. Gharani N, Waterworth DM, Batty S et al. Association of the steroid synthesis gene CYPIIa with polycystic ovary syndrome and hyperandrogenism. Human Molecular Genetics 1997; 6: 397-402.
27. Franks S, Gharani N, Waterworth D et al. The genetic basis of polycystic ovary syndrome. Human Reproduction 1997; 12: 2641-2648.
28. Waterworth DM, Bennett ST, Gharani N et al. Linkage and association of the insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 1997; 12: 2641-2648.
29. Michelmore K, Ong K, Mason S et al. Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birthweight. Clinical Endocrinology 2001; 55: 439-446.
30. Abbott DH, Dumesic DA, Eisner JR et al. Insights into the development of PCOS from studies of prenatally androgenized female rhesus monkeys. Trends in Endocrinology & Metabolism 1998; 9: 62-67.
31. Eisner JR, Dumesic DA, Kemnitz JW & Abbott DH. Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. Journal of Clinical Endocrinology & Metabolism 2000; 85: 1206-1210.
32. Birch RA, Robinson JE, Hardy K & Franks S. Morphological differences in preantral follicle distribution between normal and androgenised ovine ovaries. Endocrine Abstracts 2001; 2: abstract p74.
33. McClamrock HD & Adashi EY. Gestational hyperandrogenism. Fertility & Sterility 1992; 57: 257-274.
34. Barnes RB, Rosenfield RL, Ehrmann DA et al. Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. Journal of Clinical Endocrinology & Metabolism 1994; 79: 1328-1333.
35. Ibanez L, Potau N, Marcos MV & de Zegher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia and hyperinsulinemia in nonobese, adolescent girls: effect of flutamide. Journal of Clinical Endocrinology & Metabolism 2000; 85: 3251-3255.
36. Taylor AE. Insulin-lowering medications in polycystic ovary syndrome. Obstetrics and Gynecology Clinics of North America 2000; 27: 583-595.
37. Glueck CJ, Wang P, Fontaine R et al. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome. Journal of Adolescent Health 2001; 29: 160-169.